Core Viewpoint - Petco Health and Wellness Company, Inc. is facing a class action securities lawsuit due to alleged securities fraud that affected investors between January 14, 2021, and June 5, 2025 [1] Group 1: Lawsuit Details - The lawsuit claims that Petco's pandemic-related advantages were not sustainable and that its business model, which focuses on premium pet food, was overstated [2] - It is alleged that the defendants downplayed the severity of issues affecting Petco's business and the necessary changes to address these issues, which could negatively impact comparable sales [2] - The lawsuit asserts that the defendants misrepresented Petco's ability to achieve sustainable and profitable growth, leading to materially false and misleading public statements [2] Group 2: Next Steps for Investors - Investors who suffered losses in Petco during the specified timeframe have until August 29, 2025, to request appointment as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3] - Class members may be entitled to compensation without any out-of-pocket costs or fees, with no obligation to participate [3] Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has extensive experience in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [4]

Group 1 - Pomerantz LLP is investigating claims on behalf of Duolingo investors regarding potential securities fraud or unlawful business practices by the company and its officers [1] - JMP Securities has lowered its price target for Duolingo stock from $475 to $450 due to concerns about slowing user engagement, with daily active user growth decelerating to approximately 39% year-over-year in Q2 from about 51% in Q1 [3] - Following the news of the lowered price target, Duolingo's stock price fell by $23.60 per share, or 6.48%, closing at $340.49 on July 28, 2025 [3] Group 2 - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Legal Proceedings - Investors have until September 22, 2025, to request to lead the case, which is currently pending in the U.S. District Court for the Central District of California under the caption Makaveev v. RxSight, Inc., et al. [2]. Financial Performance - The company experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors despite claims of strong sales [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against Lineage, Inc. alleging securities fraud related to its initial public offering (IPO) on July 26, 2024 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased Lineage common stock in connection with the IPO [2]. - The complaint alleges that Lineage made false statements regarding its financial health, including claims of stable revenue growth and high occupancy rates, which were not reflective of the actual stagnant or declining performance [3]. Group 2: Allegations Against Lineage - The lawsuit claims that Lineage was experiencing a decline in customer demand due to increased cold-storage supply and a shift in customer inventory management post-COVID-19 [3]. - It is alleged that Lineage implemented unsustainable price increases prior to the IPO, which could not be maintained in the face of weakening demand [3]. - The company purportedly failed to counteract adverse trends through operational efficiencies or competitive advantages, leading to materially impaired financial results and business operations [3]. Group 3: Next Steps for Investors - Investors who suffered losses during the relevant timeframe have until September 30, 2025, to request appointment as lead plaintiff in the lawsuit [4]. - Participation in the lawsuit does not require any out-of-pocket costs for class members [4]. Group 4: Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [5]. - The firm has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [5].

NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Flywire Corporation ("Flywire Corporation" or the "Company") (NASDAQ: FLYW) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Flywire Corporation investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslr ...

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP ("XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP" or the "Company") (NYSE: XIFR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of XPLR Infrastructure, LP f/k/a Nextera Energy Partners, LP investors who were adversely affected by alleged securities fraud between September 27, 2023 and January 27, 2025. Fo ...

NEW YORK, Aug. 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Flywire Corporation ("Flywire Corporation" or the "Company") (NASDAQ: FLYW) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Flywire Corporation investors who were adversely affected by alleged securities fraud between February 28, 2024 and February 25, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/fly ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit, titled Makaveev v. RxSight, Inc., et al., is pending in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, led to another 38% decline in stock price, dropping from $12.79 to $7.95 per share [6].

Core Viewpoint - A class action securities lawsuit has been filed against Novo Nordisk A/S, alleging securities fraud that negatively impacted investors between May 7, 2025, and July 28, 2025 [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Novo Nordisk made overly positive statements while concealing material adverse facts about its growth potential, particularly regarding the compounded GLP-1 market and the likelihood of patients switching to its branded alternatives [2]. - On July 29, 2025, Novo announced a reduction in its sales and profit outlook for the second half of 2025, attributing this to lower growth expectations for its products Wegovy and Ozempic, due to competition and the persistent use of compounded GLP-1s [2]. - Following the announcement, Novo's stock price plummeted from $69.00 per share on July 28, 2025, to $53.94 per share on July 29, 2025, marking a decline of approximately 21.83% in one day [2]. Group 2: Legal Process and Participation - Investors who suffered losses during the specified timeframe have until September 30, 2025, to request to be appointed as lead plaintiff, although participation in any recovery does not require serving as a lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees, and there is no obligation to participate [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States, with over 70 employees dedicated to serving clients [4].

Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. due to alleged securities fraud affecting investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Allegations - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products [2]. - The company is unlikely to meet its previously issued financial guidance for fiscal year 2025 as a result of these issues [2]. - Positive statements made by the defendants regarding the company's business and prospects were materially misleading and lacked a reasonable basis [2]. Group 2: Legal Process - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request to be appointed as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a strong track record, having secured hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the United States [4].